Dr. Delivanis on Pembrolizumab-Induced Thyroiditis
Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
Danae Delivanis, MD, Division of Endocrinology, Diabetes, Metabolism, and Nutrition at Mayo Clinic, discusses pembrolizumab-induced thyroiditis in patients with cancer.
A retrospective comprehensive study looked at 94 patients, all who received the immune checkpoint inhibitor pembrolizumab for the treatment of their cancer, to determine how many experienced the side effect of thyroiditis.
In the study, the incidence of any thyroid abnormality was as high as 15%, says Delivanis. Of the 14 patients that experienced thyroid abnormality there were 7 cases of thyroiditis, 4 cases of new-onset or subclinical hypothyroidism, and three cases of recurrent hypothyroidism that required adjustments in treatment.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
